v3.26.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Operating Segment (Details)
3 Months Ended
Mar. 31, 2026
USD ($)
segment
Mar. 31, 2025
USD ($)
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES    
Number of reportable segments | segment 1  
Number of operating segments | segment 1  
Total research and development expenses $ 3,433,762 $ 2,374,139
Single reportable segment    
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES    
External clinical development expenses 2,483,466 1,697,229
Personnel related and stock-based compensation 722,257 429,418
Other research and development expenses 228,040 247,492
Total research and development expenses $ 3,433,763 $ 2,374,139